<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001427</url>
  </required_header>
  <id_info>
    <org_study_id>950056</org_study_id>
    <secondary_id>95-C-0056</secondary_id>
    <nct_id>NCT00001427</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin</brief_title>
  <official_title>A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to determine the response rate to 9-AC in patients with&#xD;
      advanced ovarian cancer who have recurrent disease after paclitaxel- and cisplatin-based&#xD;
      chemotherapy regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II study of 9-aminocamptothecin (9-AC), administered as an intravenous&#xD;
      continuous infusion over 72 hours with G-CSF support for patients with advanced refractory&#xD;
      ovarian cancer. The objectives of the present study are to determine the response rate to&#xD;
      9-AC in patients with advanced ovarian cancer who have recurrent disease after paclitaxel-&#xD;
      and cisplatin-based chemotherapy regimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1995</start_date>
  <completion_date>April 2000</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>9-aminocamptothecin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically proven, advanced epithelial ovarian cancer.&#xD;
&#xD;
        Histologic confirmation by Pathology Department, NIH, required.&#xD;
&#xD;
        Recurrent disease after paclitaxel and either cisplatin or carboplatin. Combination&#xD;
        platinum/paclitaxel acceptable.&#xD;
&#xD;
        Bidimensionally measurable disease on physical exam, radiographs, or peritoneoscopy. Repeat&#xD;
        peritoneoscopy after 8 courses of therapy required if documentation of disease was solely&#xD;
        by peritoneoscopy.&#xD;
&#xD;
        Laparotomy not required.&#xD;
&#xD;
        No CNS metastasis.&#xD;
&#xD;
        No borderline or mixed histology.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        See Disease Characteristics.&#xD;
&#xD;
        More than 4 weeks since any prior therapy and recovered.&#xD;
&#xD;
        No prior camptothecin analogue-based chemotherapy.&#xD;
&#xD;
        No prior radiotherapy except intraperitoneal 32-P.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Performance status: ECOG 0-2.&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
        WBC greater than 3,000.&#xD;
&#xD;
        AGC greater than 1,500.&#xD;
&#xD;
        Platelets at least 100,000.&#xD;
&#xD;
        Hemoglobin greater than 9 g/dL OR;&#xD;
&#xD;
        Hematocrit greater than 27 g/dL.&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
        Bilirubin no greater than 1.5 mg/dL.&#xD;
&#xD;
        Serum transaminases no greater than 2 times normal.&#xD;
&#xD;
        Renal:&#xD;
&#xD;
        24-hour creatinine clearance greater than 45 mL/min (documented by NCI investigator or&#xD;
        primary care physician).&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
        No myocardial infarction within 12 months.&#xD;
&#xD;
        No active congestive heart failure.&#xD;
&#xD;
        No heart block.&#xD;
&#xD;
        No arrhythmia requiring medication.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        No active uncontrolled infection.&#xD;
&#xD;
        No known HIV positivity.&#xD;
&#xD;
        No second malignancy currently under treatment except: Local basal cell carcinoma of the&#xD;
        skin, Cervical carcinoma in situ, Other malignancies (e.g., stage I breast cancer) eligible&#xD;
        at the discretion of the principal or associate investigators.&#xD;
&#xD;
        No pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials with the topoisomerase I inhibitors. Semin Oncol. 1992 Dec;19(6):663-9.</citation>
    <PMID>1334279</PMID>
  </reference>
  <reference>
    <citation>Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):16-20. doi: 10.1200/JCO.1992.10.1.16.</citation>
    <PMID>1309380</PMID>
  </reference>
  <verification_date>January 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Pharmacodynamic Studies</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>9-aminocamptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

